Traders should monitor early commercial uptake metrics and prescription trends for TONMYA, as successful market penetration could significantly revalue this small-cap biotech. The durability of clinical response and favorable pharmacokinetic profile may differentiate it from prior treatments and drive adoption despite existing alternatives.
Price Chart
Executive Summary
Tonix Pharmaceuticals announced the publication of pharmacokinetic data supporting TONMYA (cyclobenzaprine HCl sublingual tablets), the first new FDA-approved treatment for fibromyalgia in over 15 years, highlighting its unique formulation that enables rapid absorption and reduced production of an active metabolite linked to diminished long-term efficacy. The drug, commercially launched in November 2025, is designed to provide durable analgesic effects with improved tolerability.
Key Facts
- TONMYA was FDA-approved on August 15, 2025, for fibromyalgia in adults and commercially launched in November 2025.
- It is the first new prescription medicine approved for fibromyalgia in more than 15 years.
- Pharmacokinetic studies show TONMYA achieves 154% higher relative bioavailability and 783% higher dose-normalized AUC in the first hour vs. oral cyclobenzaprine due to transmucosal delivery enabled by a proprietary basifying agent.
- TONMYA reduces exposure to norcyclobenzaprine, a long half-life active metabolite believed to undermine the durability of oral cyclobenzaprine’s effect.
- Patents provide U.S. market exclusivity until 2034/2035.
- Phase 3 studies confirm durable analgesic benefit and general tolerability, with most adverse events being mild or moderate.
Financial Impact
Potential for meaningful revenue growth as TONMYA targets a chronic condition affecting 6–12 million U.S. adults with high unmet need; no specific sales figures disclosed yet.
Risk Factors
- Commercial execution risk: As a newly launched product, TONMYA faces challenges in physician adoption, payer reimbursement, and patient access.
- Safety monitoring: Boxed warnings for serotonin syndrome and embryofetal toxicity may limit use in certain populations.
- Competition: Existing off-label and branded therapies (e.g., pregabalin, duloxetine) dominate the market and may hinder uptake.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250690 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | Press Release | $5.73 | awaiting T+20 | — | $5.30 (−7.50%) |
Oct 15, 2026 12d ago | 8-K | $6.42 | awaiting T+20 | — | $5.30 (−17.45%) |
Oct 2, 2026 24d ago | 8-K | $8.07 | awaiting T+20 | — | $5.30 (+34.32%) |
Sep 22, 2026 5w ago | 8-K | $10.59 $5.78 | ▼ −45.42% | ▼ −44.86% | $5.30 (−49.95%) |
Sep 8, 2026 7w ago | 8-K | $13.16 $7.70 | ▼ −41.49% | ▼ −43.46% | $5.30 (−59.73%) |
Aug 10, 2026 11w ago | 8-K | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.30 (−57.90%) |
Aug 10, 2026 11w ago | Press Release | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.30 (−57.90%) |
Aug 3, 2026 12w ago | 8-K | $10.67 $14.10 | ▲ +32.15% | ▲ +30.91% | $5.30 (−50.33%) |
Jul 27, 2026 13w ago | Press Release | $10.37 $12.45 | ▲ +20.06% | ▲ +16.76% | $5.30 (−48.89%) |
Jul 13, 2026 15w ago | 8-K | $11.71 $12.59 | ▲ +7.56% | ▲ +4.38% | $5.30 (−54.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers